{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-16T19:06:09.085271+00:00","published_at":"2026-10-16T13:52:50.363049+00:00","section":"events","data":{"state":"PUBLISHED","derivation_version":"alpha-governance-event-derivation-v2","events":[{"event_id":"alpha:event:transition:ikmjzn1o98zyv","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-29","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:andrew-p-combs-ph-d","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:4895bb0e9a6c79d01bd4893671bb47ae2ad329a79097e842b563decb35a0d91e"],"summary":"Andrew P. Combs, Ph.D. executive of Prelude Therapeutics Inc, effective 2026-04-29.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:dtqva41u13b7i","event_type":"CFO_CHANGED","effective_at":"2026-04-29","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:bryant-d-lim-j-d","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:13"],"evidence_ids":["alpha:projection-evidence:document:7571badb040e02245418faca9e715d9af88aa9deb09635bfab42e6dc616774bd"],"summary":"Bryant D. Lim, J.D. executive of Prelude Therapeutics Inc, effective 2026-04-29.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:uyeg77ag3t75","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-29","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:charles-q-morris-m-d","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:14"],"evidence_ids":["alpha:projection-evidence:document:bf2cf1d8fd8c2ab6f69c5f0beb70c126b5a8473741b8373314454cc6c77e826b"],"summary":"Charles Q. Morris, M.D. executive of Prelude Therapeutics Inc, effective 2026-04-29.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1jcr3rj1v5qhpf","event_type":"CEO_CHANGED","effective_at":"2026-04-29","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:krishna-vaddi-ph-d","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:15"],"evidence_ids":["alpha:projection-evidence:document:fa9e3c5437d73edbd0010a254717774b12391b8275eb495fac432e7ca215645f"],"summary":"Krishna Vaddi, Ph.D. executive of Prelude Therapeutics Inc, effective 2026-04-29.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1nqkfvh1gelyjl","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-29","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:peggy-a-scherle-ph-d","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:16"],"evidence_ids":["alpha:projection-evidence:document:f4c994416c094649f8147e61bd7dc2ef7ba4f9dd2527d187c7fb3d9614ea025d"],"summary":"Peggy A. Scherle, Ph.D. executive of Prelude Therapeutics Inc, effective 2026-04-29.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:19djtrb1gi4xpp","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-29","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:sean-p-brusky-mba","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:17"],"evidence_ids":["alpha:projection-evidence:document:a5f6c6d31ed8dbd7b386d161c44e4cf77322094c10f293c329edd1dd2ca5e637"],"summary":"Sean P. Brusky, MBA executive of Prelude Therapeutics Inc, effective 2026-04-29.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1utfpph141zbvt","event_type":"DIRECTOR_APPOINTED","effective_at":"2021-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:martin-babler","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:9"],"evidence_ids":["alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60"],"summary":"Martin Babler seat on Prelude Therapeutics Inc, effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:6a4coick9l6y","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2021-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:martin-babler","alpha:committee:prelude-therapeutics-inc:audit"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:committee_record:18"],"evidence_ids":["alpha:projection-evidence:8a70bd32899c4605d3055ddd667a3912302f0f2fbcf80a2c016cf48d4983ae5a"],"summary":"Martin Babler member of Audit, effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:w859bretmqjh","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:mardi-c-dier","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60"],"summary":"Mardi Dier seat on Prelude Therapeutics Inc, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:d4nr1zl4fxy5","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:victor-sandor-m-d-c-m","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60"],"summary":"Victor Sandor, M.D.C.M. seat on Prelude Therapeutics Inc, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:16fmpth1xznsvd","event_type":"COMMITTEE_CREATED","effective_at":"2020-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:committee:prelude-therapeutics-inc:audit-chair-compensation","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60"],"summary":"Audit · Chair; Compensation committee of Prelude Therapeutics Inc, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1j4ytqntxab6l","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2020-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:mardi-c-dier","alpha:committee:prelude-therapeutics-inc:audit-chair-compensation"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60"],"summary":"Mardi Dier member of Audit · Chair; Compensation, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1kq2rzfmyag9h","event_type":"DIRECTOR_APPOINTED","effective_at":"2016-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:david-p-bonita-m-d","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60"],"summary":"David P. Bonita, M.D. seat on Prelude Therapeutics Inc, effective 2016-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:y6i3l514rkt27","event_type":"DIRECTOR_APPOINTED","effective_at":"2016-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:krishna-vaddi-ph-d","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60"],"summary":"Krishna Vaddi, Ph.D. seat on Prelude Therapeutics Inc, effective 2016-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:ssydil1ihlp6d","event_type":"DIRECTOR_APPOINTED","effective_at":"2016-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:paul-a-friedman-m-d","alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb"],"caused_claim_ids":["alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:10"],"evidence_ids":["alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60"],"summary":"Paul A. Friedman, M.D. seat on Prelude Therapeutics Inc, effective 2016-01-01.","derivation":"temporal_relationship_change"}]},"claims":[{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:5","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:david-p-bonita-m-d","object_label":"David P. Bonita, M.D.","object_source_name_forms":[],"value":"David P. Bonita, M.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:david-p-bonita-m-d","name":"David P. Bonita, M.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2016-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2016-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Prelude Therapeutics Inc DEF 14A 2025-04-29","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm","source_date":"2025-04-29","retrieved_at":"2026-04-28T23:35:02.22+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-29","effective_from":"2016-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:7","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:krishna-vaddi-ph-d","object_label":"Krishna Vaddi, Ph.D.","object_source_name_forms":[],"value":"Krishna Vaddi, Ph.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:krishna-vaddi-ph-d","name":"Krishna Vaddi, Ph.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2016-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2016-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Prelude Therapeutics Inc DEF 14A 2025-04-29","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm","source_date":"2025-04-29","retrieved_at":"2026-04-28T23:35:02.22+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-29","effective_from":"2016-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:8","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:mardi-c-dier","object_label":"Mardi Dier","object_source_name_forms":[],"value":"Mardi Dier: Director, Audit · Chair; Compensation","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:mardi-c-dier","name":"Mardi Dier"},"title":"Director","role_category":"director","committee":"Audit · Chair; Compensation","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Prelude Therapeutics Inc DEF 14A 2025-04-29","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm","source_date":"2025-04-29","retrieved_at":"2026-04-28T23:35:02.22+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-29","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:9","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:martin-babler","object_label":"Martin Babler","object_source_name_forms":[],"value":"Martin Babler: Director, Audit","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:martin-babler","name":"Martin Babler"},"title":"Director","role_category":"director","committee":"Audit","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Prelude Therapeutics Inc DEF 14A 2025-04-29","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm","source_date":"2025-04-29","retrieved_at":"2026-04-28T23:35:02.22+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-29","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:10","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:paul-a-friedman-m-d","object_label":"Paul A. Friedman, M.D.","object_source_name_forms":[],"value":"Paul A. Friedman, M.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:paul-a-friedman-m-d","name":"Paul A. Friedman, M.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2016-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2016-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Prelude Therapeutics Inc DEF 14A 2025-04-29","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm","source_date":"2025-04-29","retrieved_at":"2026-04-28T23:35:02.22+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-29","effective_from":"2016-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:11","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:victor-sandor-m-d-c-m","object_label":"Victor Sandor, M.D.C.M.","object_source_name_forms":[],"value":"Victor Sandor, M.D.C.M.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:victor-sandor-m-d-c-m","name":"Victor Sandor, M.D.C.M."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Prelude Therapeutics Inc DEF 14A 2025-04-29","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm","source_date":"2025-04-29","retrieved_at":"2026-04-28T23:35:02.22+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-04-29","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:12","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:andrew-p-combs-ph-d","object_label":"Andrew P. Combs, Ph.D.","object_source_name_forms":[],"value":"Andrew P. Combs, Ph.D.: Chief Chemistry Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:andrew-p-combs-ph-d","name":"Andrew P. Combs, Ph.D."},"title":"Chief Chemistry Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-29","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-29","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:4895bb0e9a6c79d01bd4893671bb47ae2ad329a79097e842b563decb35a0d91e","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:42.619005+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-29T00:00:00+00:00","effective_from":"2026-04-29","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:13","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:bryant-d-lim-j-d","object_label":"Bryant D. Lim, J.D.","object_source_name_forms":[],"value":"Bryant D. Lim, J.D.: Chief Legal Officer, Corporate Secretary, and Chief Financial Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:bryant-d-lim-j-d","name":"Bryant D. Lim, J.D."},"title":"Chief Legal Officer, Corporate Secretary, and Chief Financial Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-29","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-29","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:7571badb040e02245418faca9e715d9af88aa9deb09635bfab42e6dc616774bd","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:41.394073+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-29T00:00:00+00:00","effective_from":"2026-04-29","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:14","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:charles-q-morris-m-d","object_label":"Charles Q. Morris, M.D.","object_source_name_forms":[],"value":"Charles Q. Morris, M.D.: Chief Medical Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:charles-q-morris-m-d","name":"Charles Q. Morris, M.D."},"title":"Chief Medical Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-29","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-29","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:bf2cf1d8fd8c2ab6f69c5f0beb70c126b5a8473741b8373314454cc6c77e826b","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:43.805927+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-29T00:00:00+00:00","effective_from":"2026-04-29","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:15","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:krishna-vaddi-ph-d","object_label":"Krishna Vaddi, Ph.D.","object_source_name_forms":[],"value":"Krishna Vaddi, Ph.D.: Chief Executive Officer and Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:krishna-vaddi-ph-d","name":"Krishna Vaddi, Ph.D."},"title":"Chief Executive Officer and Director","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-29","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-29","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:fa9e3c5437d73edbd0010a254717774b12391b8275eb495fac432e7ca215645f","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:40.746199+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-29T00:00:00+00:00","effective_from":"2026-04-29","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:16","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:peggy-a-scherle-ph-d","object_label":"Peggy A. Scherle, Ph.D.","object_source_name_forms":[],"value":"Peggy A. Scherle, Ph.D.: Chief Scientific Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:peggy-a-scherle-ph-d","name":"Peggy A. Scherle, Ph.D."},"title":"Chief Scientific Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-29","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-29","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:f4c994416c094649f8147e61bd7dc2ef7ba4f9dd2527d187c7fb3d9614ea025d","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:42.009556+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-29T00:00:00+00:00","effective_from":"2026-04-29","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:leadership_role:17","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:sean-p-brusky-mba","object_label":"Sean P. Brusky, MBA","object_source_name_forms":[],"value":"Sean P. Brusky, MBA: Chief Business Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:sean-p-brusky-mba","name":"Sean P. Brusky, MBA"},"title":"Chief Business Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-29","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-29","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:a5f6c6d31ed8dbd7b386d161c44e4cf77322094c10f293c329edd1dd2ca5e637","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:43.205508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-29T00:00:00+00:00","effective_from":"2026-04-29","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb:committee_record:18","subject_id":"alpha:company:ed6dd5a8-73ec-4cb4-8532-7ab80167abeb","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Audit: Chair Mardi Dier; Members Mardi Dier (Chair); Martin Babler","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Audit","canonical_type":"audit","chair":"Mardi Dier","members":[{"display_name":"Mardi Dier","person_slug":"mardi-c-dier","is_chair":true},{"display_name":"Martin Babler","person_slug":"martin-babler","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:8a70bd32899c4605d3055ddd667a3912302f0f2fbcf80a2c016cf48d4983ae5a","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:3f5c4c4e10ca3850352c81863e45108e75411b25d5191fde43ca32a250b42f60","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Prelude Therapeutics Inc DEF 14A 2025-04-29","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm","source_date":"2025-04-29","retrieved_at":"2026-04-28T23:35:02.22+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:4895bb0e9a6c79d01bd4893671bb47ae2ad329a79097e842b563decb35a0d91e","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:42.619005+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:7571badb040e02245418faca9e715d9af88aa9deb09635bfab42e6dc616774bd","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:41.394073+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:bf2cf1d8fd8c2ab6f69c5f0beb70c126b5a8473741b8373314454cc6c77e826b","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:43.805927+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:fa9e3c5437d73edbd0010a254717774b12391b8275eb495fac432e7ca215645f","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:40.746199+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:f4c994416c094649f8147e61bd7dc2ef7ba4f9dd2527d187c7fb3d9614ea025d","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:42.009556+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:a5f6c6d31ed8dbd7b386d161c44e4cf77322094c10f293c329edd1dd2ca5e637","identity_scope":"source_document_reference","source_type":"sec_filing","title":"PRLD DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm","source_date":"2026-04-29T00:00:00+00:00","retrieved_at":"2026-05-16T07:07:43.205508+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:8a70bd32899c4605d3055ddd667a3912302f0f2fbcf80a2c016cf48d4983ae5a","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.843,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.896,"cross_source_agreement":0.75,"temporal_completeness":0.667},"diagnostics":{"published_claims":25,"factual_claims":25,"claims_with_linked_evidence":25,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":18,"temporal_claims_with_valid_from":12,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-16T13:52:50.363049+00:00","observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":"2026-10-16T13:52:50.363049+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":25,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/prelude-therapeutics-inc/events","section":"events","href":"https://registry.alpha.ac/api/public/companies/prelude-therapeutics-inc?format=record&section=events","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}